HomeCompareIMQCF vs ABBV

IMQCF vs ABBV: Dividend Comparison 2026

IMQCF yields 6.34% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMQCF wins by $24535.54M in total portfolio value
10 years
IMQCF
IMQCF
● Live price
6.34%
Share price
$5.45
Annual div
$0.35
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24535.65M
Annual income
$23,814,212,962.43
Full IMQCF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — IMQCF vs ABBV

📍 IMQCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMQCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMQCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMQCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMQCF
Annual income on $10K today (after 15% tax)
$539.01/yr
After 10yr DRIP, annual income (after tax)
$20,242,081,018.07/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, IMQCF beats the other by $20,242,059,491.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMQCF + ABBV for your $10,000?

IMQCF: 50%ABBV: 50%
100% ABBV50/50100% IMQCF
Portfolio after 10yr
$12267.88M
Annual income
$11,907,119,143.60/yr
Blended yield
97.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IMQCF
Analyst Ratings
3
Buy
2
Sell
Consensus: Buy
Altman Z
0.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMQCF buys
0
ABBV buys
0
No recent congressional trades found for IMQCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMQCFABBV
Forward yield6.34%3.09%
Annual dividend / share$0.35$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$24535.65M$103.7K
Annual income after 10y$23,814,212,962.43$25,324.79
Total dividends collected$24485.82M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: IMQCF vs ABBV ($10,000, DRIP)

YearIMQCF PortfolioIMQCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,968$1,268.26$11,555$434.96+$413.00IMQCF
2$15,643$2,837.16$13,485$635.47+$2.2KIMQCF
3$23,670$6,931.47$15,933$937.67+$7.7KIMQCF
4$44,930$19,603.72$19,118$1,400.80+$25.8KIMQCF
5$117,631$69,555.47$23,384$2,125.24+$94.2KIMQCF
6$466,242$340,376.56$29,290$3,286.81+$437.0KIMQCF
7$3,020,591$2,521,712.41$37,776$5,205.38+$2.98MIMQCF
8$33,768,772$30,536,739.61$50,495$8,488.44+$33.72MIMQCF
9$674,237,718$638,105,132.10$70,497$14,346.44+$674.17MIMQCF
10$24,535,647,321$23,814,212,962.43$103,718$25,324.79+$24535.54MIMQCF

IMQCF vs ABBV: Complete Analysis 2026

IMQCFStock

Inmobiliaria Colonial is the leading platform in the prime commercial real estate market in Europe, with a presence in the main business areas of Barcelona, Madrid and Paris. It owns a unique portfolio of commercial properties totaling more than 1 million m2, with a market value exceeding EUR 11.8 billion. The Group follows a dedicated long-term strategy focused on value creation through a high-quality client portfolio and asset appreciation. Looking ahead, the Colonial Group will continue to lead the urban transformation of city centers in the European market, recognized for its experience and professionalism, financial strength and profitability, while providing excellent sustainable real estate solutions adapted to the needs of its clients.

Full IMQCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IMQCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMQCF vs SCHDIMQCF vs JEPIIMQCF vs OIMQCF vs KOIMQCF vs MAINIMQCF vs JNJIMQCF vs MRKIMQCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.